Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells Lena Avinery; Danielle Regev; Hazem Khamaisi; Jacob Gopas; Jamal Mahajna;

REVERSAL OF ACCELERATED PHASE CML WITH HIGH BLAST COUNT FOLLOWING 5+2 CHEMOTHERAPY AND DASATINIB: A CASE REPORT Bü¿ra Akdo¿an; Ali Turunç; Birol Güvenç;

Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management Carla Maria Boquimpani; André Neder Ramires Abdo; Denise Pires Martins; Luciana Britto de Abreu Lima; Mayde Seadi Torriani; Israel Bendit;